title: Superficial bladder cancer treated with intravesical bacillus Calmette-Guérin or adriamycin: follow-up report.
abstract: We evaluated 139 patients with superficial bladder cancer (Stages Ta, Tl, and TIS) and treated them with either intravesical bacillus Calmette-Guérin, Tice strain (BCG), or doxorubicin hydrochloride (Adriamycin [ADR]) in a nonrandomized, multicenter study. Our follow-up study comprises 135 of these patients. Of these patients, 78 tumors were completely resected, and 61 were incompletely resected. When a proportional-hazards model (Cox) was applied, there was a statistically significant difference between the recurrence rates for the two drugs. On the basis of recurrence rates per 100 patient-months, both BCG (1.2) and ADR (0.9) worked well with completely resected tumors. However, for incomplete resections, the recurrence rate for BCG (0.9) was less than half that for ADR (1.9). The overall recurrence rates were 1.1 and 1.3 for BCG and ADR, respectively. There have been 42 failures of treatment with either BCG or ADR. We defined failure as any recurrence of tumor; progression of the cancer in stage, grade, tumor number or size; or any residual tumor after 18 treatments (14 months of therapy). As to the failures in patients whom we followed up, and whose treatment was either switched from ADR to BCG or continued on further BCG treatment, 53 per cent have achieved complete remission. Complete remission for BCG and ADR were 76 per cent and 52 per cent, respectively. Of the various factors considered in the study, only tumor grade and treatment drug were statistically significant. The cystectomy rate was 1 per cent for BCG-treated patients and 0 for ADR-treated patients.
authors.affiliation: Department of Surgery, Hahnemann University, Philadelphia, Pennsylvania.
authors.forename: O P
authors.initials: OP
authors.lastname: Khanna
authors.forename: D L
authors.initials: DL
authors.lastname: Son
authors.forename: H
authors.initials: H
authors.lastname: Mazer
authors.forename: J
authors.initials: J
authors.lastname: Read
authors.forename: D
authors.initials: D
authors.lastname: Nugent
authors.forename: R
authors.initials: R
authors.lastname: Cottone
authors.forename: M
authors.initials: M
authors.lastname: Heeg
authors.forename: M
authors.initials: M
authors.lastname: Rezvan
authors.forename: N
authors.initials: N
authors.lastname: Viek
authors.forename: R
authors.initials: R
authors.lastname: Uhlman
mesh_terms: D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D011336:Probability; D013997:Time Factors; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000601:surgery / Q000628:therapy*
chemical_list: D001500:BCG Vaccine; D004317:Doxorubicin